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Abstract
Purpose What is the level of knowledge of pharmacists
concerning pain management and the use of opioids at
the end of life, and how do they cooperate with
physicians?
Methods A written questionnaire was sent to a sample of
community and hospital pharmacists in the Netherlands.
The questionnaire was completed by 182 pharmacists
(response rate 45%).
Results Pharmacists were aware of the most basic knowl-
edge about opioids. Among the respondents, 29%
erroneously thought that life-threatening respiratory
depression was a danger with pain control, and 38%
erroneously believed that opioids were the preferred drug
for palliative sedation. One in three responding pharma-
cists did not think his/her theoretical knowledge was
sufficient to provide advice on pain control. Most
pharmacists had working agreements with physicians on
euthanasia (81%), but fewer had working agreements on
palliative sedation (46%) or opioid therapy (25%). Based
on the experience of most of responding pharmacists
(93%), physicians were open to unsolicited advice on
opioid prescriptions. The majority of community pharma-
cists (94%) checked opioid prescriptions most often only
after dispensing, while it was not a common practice
among the majority of hospital pharmacists (68%) to
check prescriptions at all.
Conclusions Although the basic knowledge of most phar-
macists was adequate, based on the responses to the
questionnaire, there seems to be a lack of knowledge in
several areas, which may hamper pharmacists in improving
the quality of care when giving advice to physicians and
preventing or correcting mistakes if necessary. If education
is improved, a more active role of the pharmacist may
improve the quality of end-of-life pharmacotherapy.
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Introduction
Pain is one of the symptoms most frequently encountered at
the end of life [1, 2], although it can be controlled
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satisfactorily in most cases if health care professionals are
adequately informed [3]. Possibilities to manage pain in
patients at the end of life have increased in the past decade,
and these possibilities have been incorporated into hand-
books and practice guidelines that were developed to support
professionals in evidence-based practice [4–6]. However, the
existence of professional guidelines does not guarantee that
this knowledge is optimally used in daily practice.
Several barriers have been identified concerning the
prescribing and use of opioids that hamper the quality of
pain management. First, there is still a lack of theoretical
knowledge about opioids among practicing physicians and
nurses [4, 7–9]. A systematic review of obstacles hindering
cancer pain management found that inadequate knowledge
was one of the most reported barriers among physicians for
adequate pain management [10]. The most reported
misconceptions were the likelihood of opioid addiction
and the belief that morphine dosage had an upper limit.
Lack of theoretical knowledge also includes rare effects of
opioids such as opioid-induced hyperalgesia [11]. Secondly,
even when health care professionals do have sufficient
theoretical knowledge about pain management guidelines,
there is no guarantee of adherence to these guidelines in
daily practice. For example, patients who clearly need
opioids for pain frequently receive dosages that are too low
[12, 13]. Another example is the prescribing of laxatives
concomitantly with opioids, a clinical guideline that has
been recommended in the World Health Organization’s
(WHO) pain ladder [6] and almost all guidelines about pain
management [4, 5, 14]. However, in daily practice, only
about half of the patients are prescribed a laxative
concomitantly [15–17]. Nearing end-of-life constipation
can still be a problem, although the patient’s deteriorating
functional status can mean management of constipation has
a lower priority. In the last days of life, when patients are no
longer able to receive oral treatment and consciousness
diminishes, oral laxatives should be discontinued [18].
Compared to physicians and nurses, surprisingly few
studies have been aimed at assessing the knowledge and
experiences of pharmacists on pain management and opioid
use. The responsibilities of pharmacists in terms of
providing pharmaceutical care vary among countries, and
hence their role in pain management may differ. In the
Netherlands, in contrast with other countries [19], pharma-
cists are not allowed to prescribe; their primary task is to
control the quality of prescribing, check for potential
interactions and support prescribers and patients with
optimal medication use [20]. Dutch hospital pharmacists
frequently contact and advise clinicians, and an increasing
number of hospital pharmacists are present in the wards for
consultation and patient education [21]. In community
pharmacy, patient education is common, and there are
regular pharmacotherapeutic audit meetings between phar-
macists and general practitioners [22]. Characteristic of the
Netherlands health care system is that euthanasia and
palliative sedation are legal options when suffering is
unbearable and hopeless [23], and most pharmacies are
prepared to fill prescriptions for euthanasia [24].
A number of studies have investigated pharmacists’
knowledge and attitudes, although none of these have been
carried out in the Netherlands. These studies have identified
a general need for more knowledge and education in pain
management [25, 26]. Misconceptions were not only
prevalent among physicians[10], but also among pharma-
cists [27]. Risk of addiction was no barrier to most
pharmacists to dispense opioids, but conservative physi-
cians and nurses and the concerns of pharmacists for
adverse effects were reported as barriers to opioid dispens-
ing [28]. Consequently, the results of these studies on
pharmacists do not support the possible assumption that
pharmacists’ knowledge is sufficient for achieving optimal
pharmacotherapy at the end of life. On the contrary, they
suggest that the pharmacist may actually be a limiting
factor in achieving optimal pharmacotherapy at the end of
life. However, note should be made of the fact that there
have not been any recent surveys performed among
pharmacists, and the previous studies were all performed
in the USA and had relatively low response rates [27, 28].
In end-of-life care, interdisciplinary cooperation among
professionals is essential [29], and within this team
approach the pharmacist has the responsibility to maintain
and optimize the quality of pharmacotherapy. Hence, it is
important that the pharmacist has an adequate and up-to-
date knowledge of pain management and the medication
involved. The aim of the study reported here was to study
the level of knowledge of pharmacists in the Netherlands
on pain management and the use of opioids at the end of
life, how they cooperate with physicians and what barriers
to good end-of-life care pharmacists experience.
Methods
Design and population
Pharmacists working as health care providers in the
Netherlands can specialize in community pharmacy or
hospital pharmacy. Both community pharmacists and
hospital pharmacists were approached to participate in this
study. Names of potential participants were retrieved
randomly from a national medical address book (BSL) that
is publicly available and contains the addresses and basic
professional qualifications of professionals working in
Dutch health care. It is updated on a yearly basis. The
random sample was taken per specialism: community
pharmacists and hospital pharmacists. Inclusion criteria
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were: working in the Netherlands as a community or
hospital pharmacist and not being in training. All the names
were first ordered by postal code (region), and then every
Nth case was sampled, with N being the number in the
sample frame divided by the desired number in the sample.
The samples were representative of the Netherlands.
The questionnaire was sent out in January 2009 followed
by two reminders. A non-response questionnaire was
enclosed with the second reminder for use in the non-
response analysis. Respondents could complete the ques-
tionnaire on paper or online. The written questionnaire was
anonymous. A separate answer card with the personal data
of the respondent could be returned to prevent further
reminders. The online questionnaire was not anonymous
because it would otherwise not be possible to exclude the
possibility that individuals who were not in the sample
would complete the questionnaire. However, when the
database was closed, the questionnaires were anonymized.
A total of 412 pharmacists were sent a questionnaire. Of
these, seven envelopes were returned to sender (respondent
had moved in the case of a private address or was no longer
working at the institution in the case of a work address). Of
the 322 community pharmacists, 147 completed the entire
questionnaire (response rate 46%). Of the 83 hospital
pharmacists, 35 completed the full questionnaire (response
rate 42%). The total overall response rate was 45%. Of the
completed questionnaires, 70% were completed in writing
and 30% were completed online. The non-response
questionnaire was completed by 35 community pharmacists
and seven hospital pharmacists.
After the closing of the data collection, a document with
the correct answers to the knowledge statements was sent
by e-mail to those who had indicated they were interested
in receiving this.
Developing the questionnaire and the pilot study
The questionnaire was developed by the authors who have
expertise in end-of-life care, pharmacy, medicine, epidemi-
ology and the development of questionnaires. Previous
studies of the knowledge or attitude concerning opioids and
pain management at the end of life were used as a reference
material [8, 30]. Questions were adapted and added with
the aim of satisfying the aims of the study and to fit the
specific situation in the Netherlands. To this end, we used
inter alia Dutch guidelines, original articles and review
articles [8, 11, 14, 31–36]. The pilot questionnaire was
tested among general practitioners (GPs) in training, elderly
care physicians in training and pharmacists. Opinions
differed on the difficulty level of the knowledge statements
in the questionnaire, but most respondents did not think the
statements were unclear or too difficult; they sometimes
even thought they were (too) easy.
The questionnaire consisted of three types of questions:
(1) knowledge statements with three options as answers:
“true”, “false” and “don’t know”; (2) experience and
attitude questions, with five options as answers: “complete-
ly agree”, “agree more than disagree”, “neutral”, “disagree
more than agree” and “completely disagree”; (3) other
questions, partly structured with four options as answers:
“often”, “sometimes”, “seldom” and “never”, and partly
semi-structured. Several questions on background were
asked, inter alia to grade one’s own knowledge about
opioids and pain management on a score of 1–10.
Analysis
We calculated descriptive statistics for the comparisons
between community pharmacists and hospital pharmacists.
Chi-square tests were used for comparing proportions
between respondents and non-respondents, using linear-
by-linear association for ordinal variables. Student’s t tests
were used for comparing means. For all tests p values are
presented. In Table 3, the categories “completely agree” and
“agree more than disagree” were merged to the category
“agree” versus the categories “neutral”, and “(completely)
disagree”.
Results
Background characteristics
In Table 1, the background characteristics of the respond-
ents are shown per specialty. Hospital pharmacists were
responsible for more patients to whom opioids were
dispensed compared to community pharmacists. They also
graded their own knowledge concerning opioids and pain
management higher.
There was one significant difference in the back-
ground characteristics between pharmacists who com-
pleted the non-response questionnaire (n=44) and those
who completed the full questionnaire (n=182). Non-
responders were more often fulltime employed (93%)
than responders (74%, data not shown). The most
important reasons for non-response were no time, too
high a workload and understaffing.
Knowledge statements
In Table 2, the answers to the knowledge statements are
shown per specialty. Of the 14 statements on knowledge
included in the questionnaire, community pharmacists gave,
on average, correct answers to between nine and ten of
these. Hospital pharmacists answered more statements
correctly (between 10 and 11). Knowledge questions for
Eur J Clin Pharmacol (2011) 67:79–89 81
which the number of correct answers was low were
“opioids may cause or worsen pain” (statement is true,
11% correct answers), “drug management of nausea in
treatment with opioids is evidence-based” (statement is
false, 19% correct answers), “simultaneous prescription of a
weak opioid (e.g. tramadol) and a strong opioid (e.g.
morphine) is contra-indicated” (statement is true, 49%
correct answers), “opioids are the favoured drugs for
palliative sedation” (statement is false, 61% correct
answers) and “life-threatening respiratory depression is a
real danger when titrating morphine to control pain”
(statement is false, 71% correct answers). Of the responding
pharmacists, 74% knew that decreased renal function could
raise the plasma concentration of morphine and its active
metabolite (morphine 6-glucuronide), and 82% calculated
an example of opioid rotation correctly.
Attitudes, experiences and barriers on pain management
Pharmacists did not think that patients always indicate their
pain to their physician (Table 3). The majority of the
pharmacists (81%) stated that an opioid prescription should
consist of both maintenance and medication as needed.
Barriers to prescribing opioids experienced by the respond-
ing pharmacists were opioid fear by the patient (79%) and
family (72%), underreporting of pain by patients (77%) and
insufficient information about the pain (60%). Practical/
logistic issues, such as problems with manufacturing/
availability and with reimbursement, were not often
experienced as obstacles to prescribing.
Attitudes and experiences on opioid rotation, tolerance,
addiction and checking prescriptions
Table 4 shows that almost 39% of the responding
pharmacists found it difficult to calculate opioid dosages
in the case of opioid rotation. Fear of addiction was seen as
a limiting factor for opioid use in daily practice (78%). The
majority of the community pharmacists (94%) checked
opioid prescriptions most often after dispensing, while the
majority of the hospital pharmacists (68%) did not check
opioid prescriptions personally. Community pharmacists
were more frequently personally involved compared to their
clinical colleagues; 15% of the community pharmacists and
none of the hospital pharmacists reported often having
personal contact with the patient/caregiver.
Table 1 Background characteristics of respondents (n=182)
Background characteristics Community pharmacists, n=147 (%) Hospital pharmacists, n=35 (%) Total, n=182 (%) p
Gender
Men 49 43 48 0.516a
Women 51 57 52
Age (years)
≤40 47 46 46 0.705b
41–50 33 37 33
51–60 19 17 19
≥61 2 0 2
Average age 42 41 42 0.818c
Employment
Full-time 78 63 74 0.054a
Part-time 22 37 26
Grade given for own knowledge before completing the questionnaire (1-10)
≤6.5 24 11 22 0.002b
6.6-7.5 52 37 50
≥7.6 24 51 29
Average grade (7.0) (7.4) (7.2) 0.003c
Number of patients to whom the respondent had dispensed opioids in 2008
None 0 0 0 0.000b
1–20 3 0 2
21–50 25 0 20
≥51 72 100 77
a χ2
b χ2 for trend. Linear by linear association
c Student’s t test
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Table 2 Answers to the knowledge statements per specialty
Knowledge statements Answersa Community pharmacists,
n=147 (%)
Hospital pharmacists,
n=35 (%)
Total, n=182 (%) p (χ2)
Pain
1. In the management of pain it is important to differentiate
between nociceptive and neuropathic pain
% true 95 97 94 0.517
% false 2 3 2
% don’t know 3 0 3
2. Administration of opioids early on in the disease
hampers good pain control later on
% true 13 3 11 0.311
% false 85 91 86
% don’t know 1 6 3
3. Opioids may cause or worsen pain % true 9 24 11 0.014
% false 65 71 66
% don’t know 26 6 23
Prescribing opioids
4. Once opioids have been started, other analgesics
should be discontinued
% true 11 0 9 0.033
% false 89 100 92
% don’t know 0 0 0
5. Opioids are only indicated for cancer patients % true 0 0 0 -
% false 100 100 100
% don’t know 0 0 0
6. Simultaneous prescription of a weak opioid (e.g. tramadol)
and a strong opioid (e.g. morphine) is contra-indicatedb
% true 50 46 49 0.675
% false 44 54 45
% don’t know 6 0 6
7. Decreased renal function raises plasma concentration
of morphine(-metabolites)
% true 72 80 74 0.196
% false 15 14 14
% don’t know 13 6 12
8. Opioids have a maximum dosage % true 11 3 10 0.163
% false 87 94 88
% don’t know 2 3 2
Side-effects
9. Life-threatening respiratory depression is a real
danger when titrating morphine to control pain
% true 24 26 25 0.702
% false 71 74 71
% don’t know 5 0 4
10. Drug management of nausea in treatment
with opioids is evidence-based
% true 45 43 44 0.893
% false 19 17 19
% don’t know 36 40 37
Opioid rotation
11. You want to change a daily dosage of 60 mg oxycodone
to an equivalent fentanyl patch. The strength of the patch isc:
% 25 μg p/h 43 65 47 0.183
% 50 μg p/h 37 24 34
% false 11 3 9
% don’t know 9 9 9
Sedation and shortening of life by opioids
12. Opioids titrated against pain, shorten life % true 1 6 2 0.685
% false 97 94 95
% don’t know 3 0 3
13. Opioids are the favoured drugs for palliative sedation % true 36 23 34 0.087
% false 59 74 61
% don’t know 5 3 4
14. Opioids are appropriate drugs to perform euthanasia % true 4 0 3 0.078
% false 94 100 95
% don’t know 1 0 2
Mean number of correct answers 9.9 10.8 10.0 0.005
a Answers are given as the percentage of respondents. Correct answer is given in bold
b A simultaneous prescription of a weak and a strong opioid is not a contra-indication in the true sense of the word. It is, however, for pharmacodynamic
reasons in general not a sensible combination. This is why it is not advocated in the available guidelines for treatment of pain
c Respondents could circle the following options 12/25/50/75/100/125/150 μg per hour or “don’t know”. With this question, two answers were considered
correct, because different guidelines give different conversions, which in turn leads to two different answers
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Cooperation with physicians through working agreements,
advice and contact over prescriptions
Table 5 shows the types of cooperation between pharma-
cists and physicians. Working arrangements with physicians
regarding euthanasia were more frequently reported by
hospital pharmacists (97%) than by community pharmacists
(77%). Working agreements concerning palliative sedation
and opioid usage were less frequent. Community pharma-
cist were more often consulted by GPs, and hospital
pharmacists by nursing home physicians and clinical
specialists. Most pharmacists (93%) reported that physi-
cians were open to unsolicited advice concerning the
opioids prescribed by the physician. Almost all pharmacists
(97%) would contact the physician if there was something
wrong with the prescription, with the most reported reasons
for contacting a physician being laxatives not prescribed
(77%), administrative incompleteness (53%) and drug–drug
interactions (52%). Most pharmacists contacted the physi-
cian when an opioid was prescribed without a laxative
(63%). Reasons for not contacting the physician were that
he/she might have had a good reason for not prescribing a
laxative or that a laxative was not needed as the patient was
terminal or being sedated. Other pharmacists dispensed a
laxative to the patient according to working agreements,
and some did not contact physicians about laxatives. Most
pharmacists (96%) did not contact the physician when an
opioid was prescribed without a prescription for an anti-
emetic drug.
Additional education
About three-quarters of the responding pharmacists (76%)
indicated that they had enough options for additional
education in subjects related to opioids and pain and
symptom management at the end of life (data not given).
Others were very adamant that there were not enough
options—neither in their region, nor non-commercial—or
information they could use in their daily practice to support
physicians.
The subjects most often mentioned in which further
education was warranted were opioid rotation (59%), pain
and symptom management in general (52%), and palliative
sedation (49%). The preferred methods to receive further
education were literature in Dutch journals (65%), confer-
ences (47%), courses on the Internet (44%) and literature in
international journals (41%).
Discussion
Although the knowledge of the majority of the respondents
was adequate on many points, by means of the questionnaire,
we were able to identify gaps in knowledge on some aspects
Table 3 Attitudes, experiences and barriers on pain management
Attitudes, experiences and barriers on pain management Community pharmacists,
n=147 (% agree)
Hospital pharmacists.
n=35 (% agree)
Total. n=182
(% agree)
p (χ2)
Pain
Good pain control is complex 84 83 84 0.981
With the current medical expertise, pain is always controllable 45 46 45 0.958
When a patient is in pain, he/she will always indicate this to his/her physician 26 17 25 0.490
I have sufficient theoretical knowledge to advise about pain control 65 80 68 0.211
Prescribing opioids
An opioid prescription should always consist of a maintenance plus as needed
medication (for break-through pain/escape)
81 83 81 0.913
Experienced barriers for good pain management
Fear for opioids by the patient 80 74 79 0.457
Underreporting of pain by patients 77 77 77 0.941
Fear for opioids by family 73 66 72 0.384
Insufficient specific information about the pain 63 46 60 0.055
Restrictive prescribing of opioids by physicians 54 57 54 0.721
Insufficient knowledge by physicians 31 51 34 0.018
Non-adherence 33 31 33 0.850
Logistic problems (e.g. possibility to use an opioid-pump at home) 10 26 13 0.011
Problems with reimbursement 7 14 8 0.156
Problems with manufacturing 5 6 5 0.829
Problems with availability of drugs 3 0 2 0.320
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of opioid use in a considerable number of the responding
pharmacists. Pharmacists answered 71% of the knowledge
questions correctly (10/14). In a number of published studies,
physicians answered between 31 and 68% questions correctly
[37–39], while in a single previous study, pharmacists
answered 46% of the questions correctly [25]. The overall
scores in different studies cannot be compared due to the
variations in the statements included in the questionnaires.
A point of concern was that only one in nine pharmacists
was aware that opioids may cause or worsen pain. This is a
rare effect and has not been known for a long time, so it is
understandable that many pharmacists are indeed unaware
of this adverse effect. However, the clinical effects can be
significant if the dose of opioids is increased instead of
decreased when a patient suffers from opioid-induced pain
sensitivity [11, 40, 41]. Although the majority of the
pharmacists stated that life-threatening respiratory depres-
sion represent no real danger to the use of opioids for pain
control [35], 25% thought it was a real danger. Many
studies have shown that this is not the case when opioids
are titrated [34], even in patients with end-of-life chronic
obstructive pulmonary disease [42].
Pharmacists would be able to support physicians in
preventing opioid over-dosage in patients with renal failure,
if they were to be aware of the fact that half-life of
morphine itself and of its active morphine 6-glucuronide is
increased in the elderly and in patients with renal
dysfunction [43]. However, only 74% of the responding
pharmacists answered this statement correctly, and for those
who did, it is not known if they actually used this
knowledge for prevention in practice. Pharmacists could
also have a role in supporting physicians with opioid
rotation. Opioid rotation is a complex procedure in which
the use of equianalgesic tables should always be accompa-
nied by clinical judgement [44]. Half of the responding
pharmacists have been occasionally/often consulted by
physicians with questions relating to opioid rotation, and
the majority of pharmacists occasionally/often advice
physicians to rotate when pain control is inadequate or
when there are side effects. However, 40% of the
pharmacists indicated they found it difficult to calculate
the correct dosage, and 18% were not able to calculate the
correct dosage when asked to do so. Opioid rotation was
also the subject that was most often mentioned by
pharmacists as an area in which they would like to receive
further education (59%).
It is crucial that pharmacists involved in end-of-life care
are aware that opioids are not the drug of choice for
Table 4 Attitudes and experiences relating to opioid rotation, tolerancea, addiction, working arrangements with physicians and controlling
prescriptions
Attitudes and experiences relating to various
aspects of opioid prescribing
Community pharmacists,
n=147 (% often/sometimes)
Hospital pharmacists,
n=35 (% often/sometimes)
Total, n=182
(% often/ sometimes)
p (χ2)
Opioid rotationb c
Physicians consult me about opioid rotation 51 54 52 0.690
I advice to rotate opioids if pain control is inadequate 64 82 67 0.111
I advice to rotate opioids in case of side-effects 61 74 63 0.310
I find calculating of opioid dosages when rotating difficult 42 26 39 0.248
Tolerance** and fear of addiction c
I think tolerance develops in the usage of opioids 84 97 87 0.055
Tolerance hampers the usage of opioids in pain control 42 31 40 0.144
Fear of addiction of patients themselves hampers the
usage of opioids in practice
77 80 78 0.890
Checking opioid prescriptions and patient contact % always/ often/ % always/often % always/often d
I personally handle opioid prescriptions and have
contact with the patient and/or his caregiver
15 0 12 0.017
I check prescriptions before dispensing 27 9 24 0.000
I check prescriptions after dispensing 94 47 85 0.000
Prescriptions are checked and dispensed
without being seen by me
8 68 20 0.016
a The following definition of tolerance was given in the questionnaire: "By tolerance for a drug we mean that a patient needs a higher dose to reach the same
pain relief while the pain stimulus remains the same. Tolerance has proven to be difficult to measure in practice, we are interested in your personal
experience."
b The following definition of opioid rotation was given in the questionnaire: "With the term ‘opioid rotation’ we mean the replacing of one opioid by
another opioid"
c Often/sometimes vs. seldom/never
d Always/often vs. sometimes/seldom/never
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palliative sedation. Approximately one in three of the
responding pharmacists thought that opioids are the
favoured drugs for palliative sedation. According to Dutch
guidelines for palliative sedation, sedation with opioids
should be considered malpractice [31]. Sedation was
mentioned by half of the pharmacists as a subject in which
they would like to receive further education.
Co-prescribing of laxatives is the most reported reason
given in this study for physician–pharmacist contact, and
63% of the pharmacists reported that not prescribing a
laxative when an opioid is prescribed is a reason for
contact. Although laxatives should not be prescribed in the
last days of life, it is important that physicians should
combine opioids with laxatives in most patients receiving
palliative care [18]. Studies have found that many patients
who are being prescribed opioids are not prescribed
laxatives concomitantly [15, 16]. Although more evidence
for the most effective laxative therapy in end-of-life care is
needed [45], checking on the concomitant use of laxatives
can improve the quality of pain management. The pharma-
cists participating in our study seldom contact physicians
on the co-prescribing of anti-emetics for the treatment or
prevention of nausea during opioid therapy. Although
nausea occurs in 15–30% of the patients receiving
morphine for cancer, this approach is understandable as it
is difficult to give advice when data on the superiority of
one anti-emetic drug over another are lacking [14]. As
nausea is common at the start of opioid therapy [46],
Table 5 Cooperation with physicians through working arrangements, advice and contact about prescriptions
Cooperative efforts with physicians Community pharmacists,
n=147
Hospital pharmacists,
n=35
Total, n=182 p (χ2)
Do you have working arrangements with physicians
about euthanasia and/or sedation and/or opioid usage?
% yes % yes % yes
Euthanasia 77 97 81 0.007
Palliative sedation 40 71 46 0.001
Opioid usage 20 46 25 0.003
None of above 22 3 18 0.010
Are you being consulted by the next physicians: %often/ sometimes % often/ sometimes % often/ sometimes
General practitioner 81 14 68 0.000
Nursing home physician 17 66 27 0.000
Clinical specialist 2 91 20 0.000
Unsolicited advice % yes % yes % yes
Are physicians open for unsolicited advice on their opioid prescription 91 100 93 0.073
Contact with physician about prescription
I will contact the prescribing physician when I think there
is something wrong with the prescription
95 97 96 0.602
Most frequently occurring reasons to contact the prescribing physician:
Laxative is not prescribed concurrently 76 77 77 0.925
Prescription writing is administratively incomplete 52 54 53 0.815
Drug interaction with opioid 51 57 52 0.493
Dosage too high 24 28 25 0.541
Supposed opioid abuse by the patient 27 3 22 0.002
Slow release preparation is not combined with immediate release 19 29 21 0.198
Dosage is too low 22 14 20 0.338
Anti-emetic is not prescribed simultaneously 7 11 8 0.376
Contact about co-prescribing of laxatives and anti-emetics
When a physician prescribes an opioid without prescribing a laxative, I always contact the prescribing physician
Yes 61 71 63 0.303a
Only for some physicians 4 12 6
No, that’s not my usual practice 35 18 31
When a physician prescribes an opioid without prescribing an anti-emetic drug, I always contact the prescribing physician
Yes 1 9 2 0.005a
Only for some physicians 1 9 2
No, that’s not my usual practice 99 83 96
a Yes vs. only for some physicians/no
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pharmacist–physician contact on nausea control is most
relevant at the initiation of opioid therapy.
Studies have shown that patients have serious concerns
regarding the use of opioids for pain relief and that these
concerns may interfere with adherence to analgesic regi-
mens [47]. The pharmacists in our study reported opioid
fear by the patient is a barrier to good pharmacotherapy,
and they also identified this fear among family members of
patients prescribed opioids. In most people with an
incurable disease preferring to remain at home during the
last stage of their lives [48], education on pain management
should not only be communicated to the patient but also to
family caregivers [49]. Financial issues were seldom seen
as a barrier, although they were acknowledged to be
important consideration during end-of-life treatment in a
previous study performed in different Western countries
[50]. In this respect, cost is not an issue in the Netherlands
as the costs of opioids are fully reimbursed by the health
care system. Given the rather good coverage of pharma-
ceuticals, availability and logistics are seldom experienced
as problematic.
Most pharmacists had working agreements with physi-
cians on euthanasia (81%); among hospital pharmacists, the
97% reporting “yes” to this question on our questionnaire
was substantially higher than 71% responding positively in
1994 [51], reflecting the practical incorporation of eutha-
nasia in the Netherlands health system. Working agree-
ments were less common for palliative sedation (46%) and/
or opioid prescribing (25%), and were more common in
hospital pharmacy than in community pharmacy. In hospital
as well as community settings, specific interventions of
pharmacists have shown to contribute to the quality of care
of patients at the end of their life [52–54]. As physicians are
generally open to receiving unsolicited advice from the
pharmacist regarding opioid prescribing (93%), specific
interventions can also be developed in the Netherlands. The
open attitude of physicians might also be the first step
towards developing local working agreements between
pharmacists and physicians for palliative sedation and pain
management.
The usual practice in the Netherlands is that community
pharmacists check all prescriptions after dispensing, where-
as hospital pharmacists often only check prescriptions “at
risk”, for example, in the case of drug–drug interactions.
Our results show, however, that one might question whether
current hospital practice is adequate given the number of
issues that warrant attention.
Strengths and limitations of this study
A major strength of this study is that it is one of the first
studies which maps the knowledge level of pharmacists
regarding the use of opioids and pain management at the
end of life. Such studies are necessary to map strengths and
weaknesses in the knowledge levels and experiences of
pharmacists and subsequently improve/add to the pharma-
cist’s level of knowledge of pharmacotherapy in end-of-life
patients. A limitation of this study is that only a limited
number of themes were assessed in which pharmacists
should have adequate knowledge, and within those themes,
not all aspects were studied. Another limitation is the
relatively poor response rate of 45%, with other pharmacy
studies reporting higher response rates [55, 56]. Our initial
sample was representative of pharmacists in the Nether-
lands, and the characteristics of responders and non-
responders were comparable, except for those in full-time
employment. This may have biased our results: full-time
pharmacists may have more experience and knowledge as
they work more hours, and the actual knowledge in this
population may be higher.
Another limitation is that some knowledge statements
and their answer categories (true or false) leave room for
interpretation. In retrospect, the statement that “simulta-
neous prescription of a weak opioid (e.g. tramadol) and a
strong opioid (e.g. morphine) is contra-indicated” may have
been more ambiguous than we intended it to be. Techni-
cally speaking, this is not a true contra-indication as it is not
a medical condition increasing the risk of a serious adverse
drug reaction. However, the addition of tramadol to
morphine is not a preferable treatment option, since it does
not reduce pain and increases side effects [57]. The
question of whether the management of nausea in treatment
with opioids is evidence based is also open to interpreta-
tion. Anti-emetics are not licensed for opioid-induced
nausea, and there is a lack of knowledge about their
efficacy in end-of-life patients [58], but there are best
practices for opioid-induced nausea [59]. We do not know
how pharmacists interpreted “evidence based”. Although
respondents of the pilot study did not make remarks with
respect to interpretation, open interpretability is relevant to
all questions—possibly most to those with a low score. In
summary, the questions have not been validated, and this
leaves room open to interpretation. However, we believe
these results do provide a good indication of the knowledge
level of pharmacists.
Conclusion
Although the effects of gaps in the knowledge of
pharmacists on opioids in clinical practice differ per
subject, we can conclude that most of the knowledge tested
in our study should be part of the basic knowledge
pharmacists should have acquired and that a gap in this
knowledge can be a barrier to providing adequate care to
the end-of-life patients. One in three pharmacists did not
Eur J Clin Pharmacol (2011) 67:79–89 87
think they had sufficient knowledge to advise on pain
control, but most were willing to follow additional
education. Physicians were open to unsolicited advice from
the pharmacist regarding opioid prescriptions. If education
is improved, pharmacists could claim a more active role in
communication with patients, caregivers and physicians to
improve the quality in end-of-life pharmacotherapy.
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